The anti‐epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab and panitumumab in combination with a chemotherapy backbone, such as FOLFIRI or FOLFOX, represent a standard of care in RAS wild type (WT) metastatic colorectal cancer (mCRC).1, 2, 3. This evidence concerns the gene EGFR and metastatic colorectal cancer.